Michael Rowe
Vorstandsvorsitzender bei EYENOVIA, INC.
Vermögen: 23 411 $ am 30.04.2024
Aktive Positionen von Michael Rowe
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
EYENOVIA, INC. | Direktor/Vorstandsmitglied | 01.08.2022 | - |
Vorstandsvorsitzender | 01.08.2022 | - | |
Geschäftsführer | 30.01.2021 | 01.08.2022 | |
Corporate Officer/Principal | 01.10.2019 | 30.01.2021 | |
Vertrieb & Marketing | 09.07.2018 | 01.10.2019 |
Karriereverlauf von Michael Rowe
Ehemalige bekannte Positionen von Michael Rowe
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
AERIE PHARMACEUTICALS, INC. | Corporate Officer/Principal | 01.02.2016 | 01.06.2018 |
ALLERGAN PLC | Corporate Officer/Principal | 01.07.2010 | 01.02.2016 |
Gene Express, Inc.
Gene Express, Inc. Miscellaneous Commercial ServicesCommercial Services Gene Express, Inc. provides research and development on molecular diagnostic products. It also provides genomic data to accelerate and enable drug and molecular diagnostic development. The company was founded in 1992 and is headquartered in Wilmington, NC. | Vertrieb & Marketing | - | - |
Ausbildung von Michael Rowe
Stony Brook University | Undergraduate Degree |
Rensselaer Polytechnic Institute | Graduate Degree |
Statistik
International
Vereinigte Staaten | 6 |
Irland | 2 |
Operativ
Corporate Officer/Principal | 3 |
Sales & Marketing | 2 |
Undergraduate Degree | 1 |
Sektoral
Health Technology | 4 |
Consumer Services | 3 |
Commercial Services | 2 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
Börsennotierte Unternehmen | 1 |
---|---|
EYENOVIA, INC. | Health Technology |
Private Unternehmen | 3 |
---|---|
Gene Express, Inc.
Gene Express, Inc. Miscellaneous Commercial ServicesCommercial Services Gene Express, Inc. provides research and development on molecular diagnostic products. It also provides genomic data to accelerate and enable drug and molecular diagnostic development. The company was founded in 1992 and is headquartered in Wilmington, NC. | Commercial Services |
Aerie Pharmaceuticals, Inc.
Aerie Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Aerie Pharmaceuticals, Inc. engages in the discovery, development, and commercialization of therapies for the treatment of patients with open-angle glaucoma, retinal diseases and other diseases of the eye. Its products include Rhopressa, Roclatan, AR-13503, and AR-1105. The company was founded by David L. Epstein, Casey C. Kopczynski, Thomas J. van Haarlem, and Eric J. Toone on January 1, 2005 and is headquartered in Durham, NCForth Worth, TX. | Health Technology |
Allergan Ltd. (Ireland)
Allergan Ltd. (Ireland) Pharmaceuticals: MajorHealth Technology Allergan Plc engages in the research, development, and manufacture of pharmaceutical products. It operates through the following business segments: US Specialized Therapeutics; US General Medicine, and International. The US Specialized Therapeutics segment includes sales and expenses relating to branded products within the United States. The US General Medicine segment involves Central Nervous System; Gastrointestinal; Women's Health; Anti-Infectives; and Diversified brands. The International segment comprises of products sold outside the United States. The company was founded in 1982 and is headquartered in Dublin, Ireland. | Health Technology |
- Börse
- Insiders
- Michael Rowe
- Erfahrung